Biomarkers for the diagnosis of new and recurrent prostate cancer

Biomarkers in Medicine

Volumn 6, Issue 5, 2012, Pages 587-596

  Sardana, Girish ^a   Diamandis, Eleftherios P ^b,c,d  

^a Ontario Cancer Biomarker Network   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

biomarkers; early detection; monitoring; predictive; prognosis; prostate cancer; prostate specific antigen

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; AUTOANTIBODY; GLUTATHIONE TRANSFERASE P1; GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; GOLM1 PROTEIN; HEPSIN; KALLIKREIN 2; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE;

BONE METASTASIS; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; DIFFERENTIAL DIAGNOSIS; EXOSOME; EZH2 GENE; FUSION GENE; GENOMICS; GLEASON SCORE; HUMAN; METABOLOMICS; PCA3 GENE; PROSTASOME; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEOMICS; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; TMPRSS2 ERG FUSION GENE; TMPRSS2 ETS FUSION GENE; TUMOR GROWTH; TUMOR RECURRENCE;

COMPUTATIONAL BIOLOGY; HUMANS; MALE; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84867632836     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.72     Document Type: Review

References (103)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10-29 (2012).
2. Novelli G, Ciccacci C, Borgiani P, Papaluca AM, Abadie E. Genetic tests and genomic biomarkers: regulation, qualifcation and validation. Clin. Cases Miner. Bone Metab. 5(2), 149-154 (2008).
3. Novelli G, Borgiani P, Ciccacci C et al Pharmacogenomics: role in medicines approval and clinical use. Public Health Genomics 13(5), 284-291 (2010).
4. DAmico F, Biancolella M, Margiotti K, Reichardt JK, Novelli G. Genomic biomarkers, androgen pathway and prostate cancer. Pharmacogenomics 8(6), 645-661 (2007). (Pubitemid 46939589)
5. McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep. 119 (2), 174-186 (2004). (Pubitemid 38661087)
6. Thompson IM, Ankerst DP, Chi C et al Operating characteristics of prostate-specifc antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294(1), 66-70 (2005). (Pubitemid 41002840)
7. Bartsch G, Horninger W, Klocker H et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int. 101(7), 809-816 (2008). (Pubitemid 351347736)
8. Labrie F, Candas B, Dupont A et al. Screening decreases prostate cancer death: frst analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 38(2), 83-91 (1999). (Pubitemid 29052946)
9. Andriole GL, Crawford ED, Grubb RL III et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360(13), 1310-1319 (2009).
10. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360(13), 1320-1328 (2009).
11. Lin K, Lipsitz R, Miller T, Janakiraman S. Benefts and harms of prostate-specifc antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann. Intern. Med. 149(3), 192-199 (2008).
12. Aihara M, Lebovitz RM, Wheeler TM et al. Prostate-specifc antigen and Gleason grade: an immunohistochemical study of prostate cancer. J. Urol. 151(6), 1558-1564 (1994). (Pubitemid 24151302)
13. Bunting PS. Screening for prostate cancer with prostate-specifc antigen: beware the biases. Clin. Chim. Acta 315(1-2), 71-97 (2002). (Pubitemid 33145250)
14. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specifc antigen level < or =4.0 ng per milliliter. N. Engl. J. Med. 350(22), 2239-2246 (2004).
15. Finne P, Auvinen A, Maattanen L et al. Diagnostic value of free prostate-specifc antigen among men with a prostate-specifc antigen level of <3.0 μ g per liter. Eur. Urol. 54(2), 362-370 (2008). (Pubitemid 351885247)
16. Stephan C, Jung K, Lein M, Diamandis EP. PSA and other tissue kallikreins for prostate cancer detection. Eur. J. Cancer 43 (13), 1918-1926 (2007). (Pubitemid 47287733)
17. Graves HC, Sensabaugh GF, Blake ET Postcoital detection of a male-specifc semen protein. Application to the investigation of rape. N. Engl. J. Med. 312(6), 338-343 (1985). (Pubitemid 15152647)
18. Iwakiri J, Granbois K, Wehner N, Graves HC, Stamey T An analysis of urinary prostate-specifc antigen before and after radical prostatectomy: evidence for secretion of prostate-specifc antigen by the periurethral glands. J. Urol. 149(4), 783-786 (1993). (Pubitemid 23111068)
19. Irani J, Salomon L, Soulie M et al. Urinary/serum prostate-specifc antigen ratio: comparison with free/total serum prostate-specifc antigen ratio in improving prostate cancer detection. Urology 65(3), 533-537 (2005). (Pubitemid 40386004)
20. Bolduc S, Lacombe L, Naud A et al. Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/ml and 10 ng/ml. Can. Urol. Assoc. J. 1(4), 377-381 (2007).
21. Bolduc S, Inman BA, Lacombe L, Fradet Y, Tremblay RR. Early detection of prostate cancer local recurrence by urinary prostate-specifc antigen. Can. Urol. Assoc. J. 3(3), 213-217 (2009).
22. Pannek J, Rittenhouse HG, Evans CL et al. Molecular forms of prostate-specifc antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. Urology 50(5), 715-721 (1997). (Pubitemid 27494992)
23. Sardana G, Diamandis EP. The kallikrein family of proteins as urinary biomarkers for the detection of prostate cancer. Clin. Biochem. 42(13-14), 1483-1486 (2009).
24. Black MH, Magklara A, Obiezu C et al. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumors and in normal breast secretions. Br. J. Cancer 82(2), 361-367 (2000). (Pubitemid 30045382)
25. Recker F, Kwiatkowski MK, Piironen T et al. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confned prostate cancer compared with prostate-specifc antigen. Urology 55(4), 481-485 (2000). (Pubitemid 30157948)
26. Stephan C, Jung K, Nakamura T et al. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. Int. J. Urol. 13(3), 238-243 (2006).
27. Haese A, Graefen M, Steuber T et al. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate-specifc antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. J. Urol. 170(6 Pt 1), 2269-2273 (2003). (Pubitemid 37413973)
28. Steuber T, Vickers AJ, Haese A et al. Risk assessment for biochemical recurrence prior to radical prostatectomy: signifcant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate-specifc antigen (PSA) in men with moderate PSA-elevation in serum. Int. J. Cancer 118(5), 1234-1240 (2006). (Pubitemid 43185611)
29. Elgamal AA, Holmes EH, Su SL et al. Prostate-specifc membrane antigen (PSMA): current benefts and future value. Semin. Surg. Oncol. 18(1), 10-16 (2000). (Pubitemid 30036115)
30. Mincheff M, Zoubak S, Makogonenko Y. Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals. Cancer Gene Ther. 13(4), 436-444 (2006).
31. Hessels D, Klein Gunnewiek JM, van Oort I et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 44(1), 8-15 (2003).
32. Bussemakers MJ, van Bokhoven A, Verhaegh GW et al. DD3: a new prostate-specifc gene, highly overexpressed in prostate cancer. Cancer Res. 59(23), 5975-5979 (1999). (Pubitemid 30004960)
33. de Kok JB, Verhaegh GW, Roelofs RW et al. DD3 (PCA3), a very sensitive and specifc marker to detect prostate tumors. Cancer Res. 62(9), 2695-2698 (2002). (Pubitemid 34462754)
34. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat. Rev. Urol. 6(5), 255-261 (2009).
35. Roobol MJ, Schroder FH, van Leenders GL et al. Performance of prostate cancer antigen 3 (PCA3) and prostate-specifc antigen in prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (100). Eur. Urol. 58(6), 893-899 (2010).
36. Haese A, de la TA, van Poppel H et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur. Urol. 54(5), 1081-1088 (2008).
37. Wang R, Chinnaiyan AM, Dunn RL, Wojno KJ, Wei JT Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 115(17), 3879-3886 (2009).
38. Nakanishi H, Groskopf J, Fritsche HA et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J. Urol. 179(5), 1804-1809 (2008).
39. Whitman EJ, Groskopf J, Ali A et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J. Urol. 180(5), 1975-1978 (2008).
40. van Gils MP, Hessels D, van Hooij O et al. The time-resolved fuorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin. Cancer Res. 13(3), 939-943 (2007). (Pubitemid 46340370)
41. Groskopf J, Aubin SM, Deras IL et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin. Chem. 52(6), 1089-1095 (2006). (Pubitemid 43794421)
42. Laxman B, Morris DS, Yu J et al A frst-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 68(3), 645-649 (2008). (Pubitemid 351206738)
43. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748), 644-648 (2005). (Pubitemid 41528150)
44. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat. Rev. Urol. 6(8), 429-439 (2009).
45. Prensner JR, Chinnaiyan AM. Oncogenic gene fusions in epithelial carcinomas. Curr. Opin. Genet. Dev. 19(1), 82-91 (2009).
46. Laxman B, Tomlins SA, Mehra R et al. Noninvasive detection of TMPRSS2-ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8(10), 885-888 (2006).
47. Demichelis F, Fall K, Perner S et al. TMPRSS2-ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26(31), 4596-4599 (2007). (Pubitemid 47037039)
48. Attard G, Clark J, Ambroisine L et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifes fatal human prostate cancer. Oncogene 27(3), 253-263 (2008).
49. Tomlins SA, Aubin SM, Siddiqui J et al. Urine TMPRSS2-ERG fusion transcript stratifes prostate cancer risk in men with elevated serum PSA. Sci. Transl. Med. 3(94), 94ra72 (2011).
50. Fine SW, Gopalan A, Leversha MA et al. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod. Pathol. 23(10), 1325-1333 (2010).
51. Gopalan A, Leversha MA, Satagopan JM et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 69(4), 1400-1406 (2009).
52. Hessels D, Smit FP, Verhaegh GW et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin. Cancer Res. 13(17), 5103-5108 (2007). (Pubitemid 47502077)
53. Shariat SF, Menesses-Diaz A, Kim IY et al. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology 63(6), 1191-1197 (2004). (Pubitemid 38746840)
54. Shariat SF, Walz J, Roehrborn CG et al. Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy. J. Urol. 179(4), 1593-1597 (2008).
55. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat. Med. 1(4), 282-284 (1995).
56. Jiang Z, Fanger GR, Woda BA et al. Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum. Pathol. 34(8), 792-796 (2003). (Pubitemid 37040616)
57. Jiang Z, Woda BA. Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy. Adv. Anat. Pathol. 11(6), 316-321 (2004).
58. Luo J, Zha S, Gage WR et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 62(8), 2220-2226 (2002). (Pubitemid 34411693)
59. Rubin MA, Zhou M, Dhanasekaran SM et al. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287(13), 1662-1670 (2002). (Pubitemid 34289218)
60. Jiang Z, Wu CL, Woda BA et al. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Histopathology 45(3), 218-225 (2004). (Pubitemid 39294698)
61. Ouyang B, Bracken B, Burke B et al. A duplex quantitative polymerase chain reaction assay based on quantifcation of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J. Urol. 181(6), 2508-2513 (2009).
62. Rogers CG, Yan G, Zha S et al. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. J. Urol. 172(4 Pt 1), 1501-1503 (2004). (Pubitemid 39249757)
63. Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419(6907), 624-629 (2002).
64. Rhodes DR, Sanda MG, Otte A P, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specifc antigen-defned recurrence of prostate cancer. J. Natl Cancer Inst. 95(9), 661-668 (2003). (Pubitemid 36603722)
65. Harden SV, Sanderson H, Goodman SN et al. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J. Natl Cancer Inst. 95(21), 1634-1637 (2003). (Pubitemid 37455931)
66. Gonzalgo ML, Nakayama M, Lee SM, De Marzo AM, Nelson WG. Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology 63(2), 414-418 (2004). (Pubitemid 38234457)
67. Crocitto LE, Korns D, Kretzner L et al. Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology 64(4), 821-825 (2004). (Pubitemid 39446082)
68. Cairns P, Esteller M, Herman JG et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res. 7(9), 2727-2730 (2001). (Pubitemid 32911377)
69. Goessl C, Krause H, Muller M et al. Fluorescent methylation-specifc polymerase chain reaction for DNA-based detection of prostate cancer in bodily fuids. Cancer Res. 60(21), 5941-5945 (2000).
70. Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin. Cancer Res. 9(7), 2673-2677 (2003). (Pubitemid 36842112)
71. Jeronimo C, Usadel H, Henrique R et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confned prostate adenocarcinoma. J. Natl Cancer Inst. 93(22), 1747-1752 (2001). (Pubitemid 33130264)
72. Goessl C, Muller M, Heicappell R et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 58(3), 335-338 (2001). (Pubitemid 32816344)
73. Woodson K, O'Reilly KJ, Hanson JC et al. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J. Urol. 179(2), 508-511 (2008).
74. Wozny W, Schroer K, Schwall GP et al. Differential radioactive quantifcation of protein abundance ratios between benign and malignant prostate tissues: cancer association of annexin A3. Proteomics 7(2), 313-322 (2007). (Pubitemid 46184093)
75. Schostak M, Schwall GP, Poznanovic S et al. Annexin A3 in urine: a highly specifc noninvasive marker for prostate cancer early detection. J. Urol. 181(1), 343-353 (2009).
76. Stephan C, Yousef GM, Scorilas A et al. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J. Urol. 171(1), 187-191 (2004). (Pubitemid 37549120)
77. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412(6849), 822-826 (2001). (Pubitemid 32801464)
78. Sreekumar A, Laxman B, Rhodes DR et al. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J. Natl Cancer Inst. 96(11), 834-843 (2004). (Pubitemid 38807604)
79. Wang X, Yu J, Sreekumar A et al. Autoantibody signatures in prostate cancer. N. Engl. J. Med. 353(12), 1224-1235 (2005). (Pubitemid 41345944)
80. Steuber T, Vickers A, Haese A et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int. J. Cancer 120(7), 1499-1504 (2007). (Pubitemid 46355384)
81. Miyake H, Hara I, Yamanaka K et al. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 39(2), 123-129 (1999). (Pubitemid 29194284)
82. Shariat SF, Roehrborn CG, McConnell JD et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J. Clin. Oncol. 25(4), 349-355 (2007). (Pubitemid 350002982)
83. Attard G, Swennenhuis JF, Olmos D et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69(7), 2912-2918 (2009).
84. Okegawa T, Nutahara K, Higashihara E. Prognostic signifcance of circulating tumor cells in patients with hormone refractory prostate cancer. J. Urol. 181(3), 1091-1097 (2009).
85. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival beneft from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14(19), 6302-6309 (2008).
86. Duijvesz D, Luider T, Bangma CH, Jenster G. Exosomes as biomarker treasure chests for prostate cancer. Eur. Urol. 59(5), 823-831 (2011).
87. Tavoosidana G, Ronquist G, Darmanis S et al. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc. Natl Acad. Sci. USA 108(21), 8809-8814 (2011).
88. Nilsson J, Skog J, Nordstrand A et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br. J. Cancer 100(10), 1603-1607 (2009).
89. Varambally S, Laxman B, Mehra R et al Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia 10(11), 1285-1294 (2008).
90. Sommerfeld HJ, Meeker AK, Piatyszek MA et al. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res. 56(1), 218-222 (1996). (Pubitemid 26011466)
91. Meid FH, Gygi CM, Leisinger HJ, Bosman FT, Benhattar J. The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage. J. Urol. 165(5), 1802-1805 (2001). (Pubitemid 32410312)
92. Ornstein DK, Tyson DR. Proteomics for the identifcation of new prostate cancer biomarkers. Urol. Oncol. 24(3), 231-236 (2006).
93. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics 1(11), 845-867 (2002).
94. Rosenzweig CN, Zhang Z, Sun X et al. Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J. Urol. 181(3), 1407-1414 (2009).
95. Zhao L, Lee BY, Brown DA et al. Identifcation of candidate biomarkers of therapeutic response to docetaxel by proteomic profling. Cancer Res. 69(19), 7696-7703 (2009).
96. Sardana G, Jung K, Stephan C, Diamandis EP. Proteomic analysis of conditioned media from the PC3, LNCa P, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J. Proteome Res. 7(8), 3329-3338 (2008).
97. Prensner JR, Iyer MK, Balbin OA et al. Transcriptome sequencing across a prostate cancer cohort identifes PCAT-1, an unannotated lincRNA implicated in disease progression. Nat. Biotechnol. 29(8), 742-749 (2011).
98. Roychowdhury S, Iyer MK, Robinson DR et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med. 3(111), 111ra121 (2011).
99. Theodorescu D, Schiffer E, Bauer HW et al. Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin. Appl. 2(556-570 (2008). (Pubitemid 351566263)
100. Rehman I, Azzouzi AR, Catto JW et al. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 64(6), 1238-1243 (2004). (Pubitemid 39647082)
101. Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profles delineate potential role for sarcosine in prostate cancer progression. Nature 457(7231), 910-914 (2009).
102. Welch HG, Black WC. Overdiagnosis in cancer. J. Natl Cancer Inst. 102(9), 605-613 (2010).
103. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classifcation or prediction: standards for study design. J. Natl Cancer Inst. 100(20), 1432-1438 (2008).